OBJECTIVE: To investigate the association of anti-hydroxymethylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy with HLA class I and II antigens. METHODS: HLA antigens were determined in 1) 20 white and 8 African American anti-HMGCR patients, 2) 487 white and 167 African American controls, and 3) 51 white subjects with mild self-limited statin intolerance. RESULTS: White anti-HMGCR patients had a higher frequency of the combination HLA-DR11, DQA5, and DQB7 than controls or statin-intolerant subjects (70% versus 17%; odds ratio [OR] 11.7 [95% confidence interval (95% CI) 4.0-35.3], P = 4.1 × 10(-7) and 70% versus 21%; OR 8.3 [95% CI 2.2-33.9], P = 5.4 × 10(-4) , respectively). This combination was not increased in African American anti-HMGCR subjects compared to controls (13% versus 3%; OR 4.6 [95% CI 0.2-53.3], P = 0.2). However, DR11 was increased in African American anti-HMGCR patients compared to controls (88% versus 21%; OR 26.4 [95% CI 3.1-590.3], P = 0.0002). High-resolution mapping showed that 95% with DR11 had DRB1*11:01. DQA1 and DQB6 were less frequent in white anti-HMGCR-positive patients compared to controls (25% versus 65%; OR 0.2 [95% CI 0.1-0.5], P = 5.5 × 10(-4) and 0% versus 45%; OR 0.0 [95% CI 0.0-0.3], P = 2.1 × 10(-5) , respectively). DRB11 was not associated with particular disease features. CONCLUSION: DRB1*11:01 is associated with an increased risk of anti-HMGCR myopathy in whites and African Americans. These findings suggest a mechanistic link between statin exposure, increased HMGCR expression, and the possible presentation of HMGCR-derived peptide(s) by DRB1*11:01.
OBJECTIVE: To investigate the association of anti-hydroxymethylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy with HLA class I and II antigens. METHODS:HLA antigens were determined in 1) 20 white and 8 African American anti-HMGCRpatients, 2) 487 white and 167 African American controls, and 3) 51 white subjects with mild self-limited statin intolerance. RESULTS: White anti-HMGCRpatients had a higher frequency of the combination HLA-DR11, DQA5, and DQB7 than controls or statin-intolerant subjects (70% versus 17%; odds ratio [OR] 11.7 [95% confidence interval (95% CI) 4.0-35.3], P = 4.1 × 10(-7) and 70% versus 21%; OR 8.3 [95% CI 2.2-33.9], P = 5.4 × 10(-4) , respectively). This combination was not increased in African American anti-HMGCR subjects compared to controls (13% versus 3%; OR 4.6 [95% CI 0.2-53.3], P = 0.2). However, DR11 was increased in African American anti-HMGCRpatients compared to controls (88% versus 21%; OR 26.4 [95% CI 3.1-590.3], P = 0.0002). High-resolution mapping showed that 95% with DR11 had DRB1*11:01. DQA1 and DQB6 were less frequent in white anti-HMGCR-positive patients compared to controls (25% versus 65%; OR 0.2 [95% CI 0.1-0.5], P = 5.5 × 10(-4) and 0% versus 45%; OR 0.0 [95% CI 0.0-0.3], P = 2.1 × 10(-5) , respectively). DRB11 was not associated with particular disease features. CONCLUSION:DRB1*11:01 is associated with an increased risk of anti-HMGCRmyopathy in whites and African Americans. These findings suggest a mechanistic link between statin exposure, increased HMGCR expression, and the possible presentation of HMGCR-derived peptide(s) by DRB1*11:01.
Authors: Merrilee Needham; Victoria Fabian; Wally Knezevic; Peter Panegyres; Paul Zilko; Frank L Mastaglia Journal: Neuromuscul Disord Date: 2007-01-22 Impact factor: 4.296
Authors: Andrew L Mammen; Tae Chung; Lisa Christopher-Stine; Paul Rosen; Antony Rosen; Kimberly R Doering; Livia A Casciola-Rosen Journal: Arthritis Rheum Date: 2011-03
Authors: Terrance P O'Hanlon; Danielle Mercatante Carrick; Ira N Targoff; Frank C Arnett; John D Reveille; Mary Carrington; Xiaojiang Gao; Chester V Oddis; Penelope A Morel; James D Malley; Karen Malley; Ejaz A Shamim; Lisa G Rider; Stephen J Chanock; Charles B Foster; Thomas Bunch; Perry J Blackshear; Paul H Plotz; Lori A Love; Frederick W Miller Journal: Medicine (Baltimore) Date: 2006-03 Impact factor: 1.889
Authors: Andrew L Mammen; Katherine Pak; Emma K Williams; Diane Brisson; Joe Coresh; Elizabeth Selvin; Daniel Gaudet Journal: Arthritis Care Res (Hoboken) Date: 2012-02 Impact factor: 4.794
Authors: Terrance P O'Hanlon; Lisa G Rider; Gulnara Mamyrova; Ira N Targoff; Frank C Arnett; John D Reveille; Mary Carrington; Xiaojiang Gao; Chester V Oddis; Penelope A Morel; James D Malley; Karen Malley; Ejaz A Shamim; Stephen J Chanock; Charles B Foster; Thomas Bunch; Ann M Reed; Lori A Love; Frederick W Miller Journal: Arthritis Rheum Date: 2006-11
Authors: Frank C Arnett; Pravitt Gourh; Sanjay Shete; Chul W Ahn; Robert E Honey; Sandeep K Agarwal; Filemon K Tan; Terry McNearney; Michael Fischbach; Marvin J Fritzler; Maureen D Mayes; John D Reveille Journal: Ann Rheum Dis Date: 2009-07-12 Impact factor: 19.103
Authors: Phyllis Grable-Esposito; Hans D Katzberg; Steven A Greenberg; Jayashri Srinivasan; Jonathan Katz; Anthony A Amato Journal: Muscle Nerve Date: 2010-02 Impact factor: 3.217
Authors: Frank L Mastaglia; Merrilee Needham; Adrian Scott; Ian James; Paul Zilko; Timothy Day; Lynette Kiers; Alastair Corbett; Campbell S Witt; Richard Allcock; Nigel Laing; Michael Garlepp; Frank T Christiansen Journal: Neuromuscul Disord Date: 2009-08-31 Impact factor: 4.296
Authors: Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson Journal: Cardiovasc Res Date: 2018-07-01 Impact factor: 10.787
Authors: Mark M Zaki; Zain M Virk; Diego Lopez; Jenna Klubnick; Jared T Ahrendsen; Hemant Varma; Vasileios Kyttaris; Ilana Abeles Journal: Eur J Rheumatol Date: 2021-01-01
Authors: Laura Nichols; Kurt Pfeifer; Andrew L Mammen; Nazima Shahnoor; Chamindra G Konersman Journal: J Gen Intern Med Date: 2015-04-09 Impact factor: 5.128